Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 9, 2008, Pages 890-895

  Grijalva, Carlos G ^a   Chung, Cecilia P ^a   Stein, C Michael ^a   Gideon, Patricia S ^a   Dyer, Shannon M ^a   Mitchel Jr , Edward F ^a   Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

Opportunistic mycoses; Pneumonia; Positive predictive values; Rheumatoid arthritis; Sepsis

Indexed keywords

ACCURACY; ADULT; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ANALYSIS; COMPUTER PREDICTION; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE EXACERBATION; DRUG SAFETY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL RECORD REVIEW; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SEPSIS; STREPTOCOCCUS INFECTION;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MEDICAID; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; UNITED STATES;

EID: 52949130584     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1625     Document Type: Article

References (16)

1. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001; 10: 389-392.
2. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004; 57: 131-141.
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376.
4. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-1133.
5. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004; 50: 1040-4050.
6. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-3443.
7. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol 2007; 60: 397-409.
8. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642-1650.
9. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-1755.
10. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
11. O'Shaughnessy EM, Shea YM, Witebsky FG. Laboratory diagnosis of invasive mycoses. Infect Dis Clin North Am 2003; 17: 135-158.
12. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
13. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-418.
14. Rothman KJ, Greenland S. Modern Epidemiology. Lippincott-Raven: Philadelphia; 1998.
15. Green MS. Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status. Am J Epidemiol 1983; 117: 98-105.
16. Curtis JR, Martin C, Saag KG, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum 2007; 57: 343-346.